Pharmaceutical Products
We strive to address unmet medical needs through excellence in science
:quality(90)/)
At Roche Pharmaceuticals, we focus on finding new medicines that help patients live longer, better lives and evolve the practice of medicine.
Below is a list of Roche medicines that are available in Aotearoa New Zealand. Use the filter function to filter by disease area to find the Data Sheet and Consumer Medicine Information (CMI) for each product.
If you have a question about a Roche medicine, please Contact Us.
For more information about Roche's Medicines and Cost Share Programmes, Healthcare Professionals can sign up on RocheHUB HCP Portal
Medsafe Registered Uses of Actemra Infusion:
Treatment of moderate to severe rheumatoid arthritis in adults, as well as certain types of systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis and certain patients with COVID-19.
Pharmac Funding Status of Actemra Infusion:
Funded Moderate to severe rheumatoid arthritis in adults
Funded Certain types of systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis
Funded Certain patients with COVID-19
See Pharmac websitefor more information.
If you would like to learn more about Actemra Infusion, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Actemra SC:
Treatment of moderate to severe rheumatoid arthritis and giant cell arteritis in adults
Pharmac Funding Status of Actemra SC:
Not Funded Moderate to severe rheumatoid arthritis in adults
Not Funded Giant cell arteritis in adults
Actemra SC is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Actemra SC, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Alecensa
Treatment of locally advanced or metastatic ALK-positive non-small cell lung cancer.
Pharmac Funding Status of Alecensa
Funded Locally advanced or metastatic ALK-positive non-small cell lung cancer
See Pharmac webisitefor more information.
If you would like to learn more about Alecensa, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Avastin
Treatment of advanced (metastatic) bowel, kidney, breast, brain, lung, ovarian and cervical cancers
Pharmac Funding Status of Avastin
Not Funded Metastatic bowel cancer
Not Funded Metastatic kidney cancer
Not Funded Metastatic breast cancer
Not Funded Metastatic brain cancer
Not Funded Metastatic lung cancer
Not Funded Metastatic ovarian cancer
Not Funded Metastatic cervical cancer
Avastin is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients. These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Avastin, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of CellCept
Treatment to prevent rejection of transplanted organs
Pharmac Funding Status of CellCept
Funded To prevent rejection of transplanted organs
See Pharmac websitefor more information.
If you would like to learn more about CellCept, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Columvi
Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT).
Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Pharmac Funding Status of Columvi
Not funded Diffuse large B cell lymphoma
Columvi isn’t funded by PHARMAC. This means that you will need to pay for it at a private treatment centre.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Columvi, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Cotellic
Treatment of advanced (metastatic) melanoma
Pharmac Funding Status of Cotellic
Not Funded Metastatic melanoma
Cotellic is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Cotellic, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Erivedge
Treatment of advanced (metastatic) basal cell carcinoma
Pharmac Funding Status of Erivedge:
Not Funded Metastatic basal cell carcinoma
Erivedge is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Erivedge, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Esbriet
Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Pharmac Funding Status of Esbriet:
Funded Idiopathic Pulmonary Fibrosis (IPF)
See Pharmac websitefor more information.
If you would like to learn more about Esbriet, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Evrysdi
Treatment of spinal muscular atrophy (SMA) in patients aged 2 months and older.
Pharmac Funding Status of Evrysdi:
Funded Spinal Muscular Atrophy 18 years old and under
Not Funded Spinal Muscular Atrophy over 18 years old
See Pharmac websitefor more information.
Evrysdi is not publicly funded by PHARMAC for all indications, which means some New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Evrysdi, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Gazyva
Treatment of previously untreated chronic lymphocytic leukaemia (CLL) and indolent non hodgkin lymphoma (iNHL)
Pharmac Funding Status of Gazyva:
Funded Previously untreated chronic lymphocytic leukaemia (CLL)
Funded Indolent non hodgkin lymphoma (iNHL)
See Pharmac websitefor more information.
If you would like to learn more about Gazyva, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Hemlibra
Treatment of congenital haemophilia A with or without factor VIII inhibitors
Pharmac Funding Status of Hemlibra:
Funded Congenital haemophilia A with factor VIII inhibitors
Funded Congenital haemophilia A without factor VIII inhibitors
See Pharmac websitefor more information.
If you would like to learn more about Hemlibra, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Herceptin SC
Treatment of HER2-positive early and metastatic breast cancer
Pharmac Funding Status of Herceptin SC:
Not Funded HER2-positive early and metastatic breast cancer
Herceptin SC is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Herceptin SC, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Herceptin IV
Treatment of HER2-positive early and metastatic breast cancer and for HER2-positive advanced gastric cancer.
Pharmac Funding Status of Herceptin IV:
Not Funded HER2-positive early and metastatic breast cancer
Not Funded HER2-positive early and metastatic breast cancer
Herceptin IV is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Herceptin IV, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Kadcyla
For the second-line treatment of HER2-positive metastatic breast cancer and adjuvant treatment in early HER2-positive breast cancer.
Pharmac Funding Status of Kadcyla:
Funded Second-line treatment of HER2-positive metastatic breast cancer
Funded Adjuvant treatment in early HER2-positive breast cancer
See Pharmac websitefor more information.
If you would like to learn more about Kadcyla, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Mabthera RA
Treatment of rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis
Pharmac Funding Status of Mabthera RA:
Funded Rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis
See Pharmac websitefor more information.
If you would like to learn more about Mabthera RA, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Madopar
Treatment of Parkinson’s disease
Pharmac Funding status of Madopar:
Funded Parkinson's Disease
See Pharmac websitefor more information.
If you would like to learn more about Madopar, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of NeoRecormon
Treatment of anaemia
Pharmac Funding Status of NeoRecormon:
Not Funded Anaemia
NeoRecormon is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about NeoRecormon, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Ocrevus IV and Ocrevus SC
Treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)
Pharmac Funding Status of Ocrevus IV:
Funded Relapsing Forms of Multiple Sclerosis (for patients who meet defined criteria)
Funded Primary Progressive Multiple Sclerosis (for patients who meet defined criteria)
Pharmac Funding Status of Ocrevus SC
Not Funded for any indication
See Pharmac websitefor more information.
If you would like to learn more about Ocrevus IV and Ocrevus SC, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Perjeta
Treatment of HER2-positive early breast cancer either before or after surgery (neoadjuvant or adjuvant) and advanced (metastatic) breast cancer
Pharmac Funding Status of Perjeta:
Not Funded HER2-positive early breast cancer either before or after surgery (neoadjuvant or adjuvant)
Funded Advanced (metastatic) breast cancer
See Pharmac websitefor more information.
Perjeta is not publicly funded by PHARMAC, which means some New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Perjeta, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Phesgo
For the treatment of HER2-positive early breast cancer and HER-2 positive metastatic or locally recurrent unresectable breast cancer, in combination with chemotherapy.
Pharmac Funding Status of Phesgo:
Not Funded HER2-positive early breast cancer and HER-2 positive metastatic or locally recurrent unresectable breast cancer, in combination with chemotherapy
Phesgo is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Phesgo, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Polivy
For the treatment of certain patients with diffuse large B-cell lymphoma
Pharmac Funding Status of Polivy:
Not Funded Certain patients with diffuse large B-cell lymphoma
Polivy is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Polivy, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Pulmozyme
Treatment of cystic fibrosis
Pharmac Funding Status of Pulmozyme:
Funded Cystic fibrosis
See Pharmac websitefor more information.
If you would like to learn more about Pulmozyme, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of ROZLYTREK
Treatment of ROS1 positive locally advanced and metastatic non-small cell lung cancer
Treatment of NTRK-fusion positive locally advanced and metastatic solid tumours
Pharmac Funding Status of ROZLYTREK:
Not Funded ROS1 positive locally advanced and metastatic non-small cell lung cancer
Not Funded Certain patients with NTRK fusion-positive locally advanced or metastatic solid tumours
ROZLYTREK is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about ROZLYTREK, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Tamiflu
Treatment of influenza
Pharmac Funding Status of Tamiflu:
National Reserve Supply (to be released for use in pandemic setting)
If you would like to learn more about Tamiflu, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Tecentriq and Tecentriq SC
Treatment of early and metastatic non-small cell lung cancer, extensive-stage small cell lung cancer, metastatic urothelial carcinoma, unresectable hepatocellular carcinoma, and metastatic triple-negative breast cancer.
Pharmac Funding Status of Tecentriq
Funded Locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received chemotherapy
Funded Hepatocellular carcinoma
Not Funded Urothelial cancer
Not Funded Triple negative breast cancer
Not Funded Other lung cancer indications
Pharmac Funding Status of Tecentriq SC
Not Funded for any indication
See Pharmac websitefor more information.
Tecentriq and Tecentriq SC are not publicly funded by PHARMAC for all indications, which means some New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Tecentriq and Tecentriq SC, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of VABYSMO
Treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and macular oedema secondary to retinal vein occlusion (RVO).
Pharmac Funding Status of VABYSMO
Not Funded Neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and macular oedema secondary to retinal vein occlusion (RVO).
VABYSMO is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about VABYSMO, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Zelboraf
Treatment of advanced (metastatic) melanoma.
Pharmac Funding Status of Zelboraf
Not Funded Advanced (metastatic) melanoma
Zelboraf is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Zelboraf, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Actemra Infusion:
Treatment of moderate to severe rheumatoid arthritis in adults, as well as certain types of systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis and certain patients with COVID-19.
Pharmac Funding Status of Actemra Infusion:
Funded Moderate to severe rheumatoid arthritis in adults
Funded Certain types of systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis
Funded Certain patients with COVID-19
See Pharmac websitefor more information.
If you would like to learn more about Actemra Infusion, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Actemra SC:
Treatment of moderate to severe rheumatoid arthritis and giant cell arteritis in adults
Pharmac Funding Status of Actemra SC:
Not Funded Moderate to severe rheumatoid arthritis in adults
Not Funded Giant cell arteritis in adults
Actemra SC is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Actemra SC, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Mabthera RA
Treatment of rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis
Pharmac Funding Status of Mabthera RA:
Funded Rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis
See Pharmac websitefor more information.
If you would like to learn more about Mabthera RA, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Columvi
Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT).
Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Pharmac Funding Status of Columvi
Not funded Diffuse large B cell lymphoma
Columvi isn’t funded by PHARMAC. This means that you will need to pay for it at a private treatment centre.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Columvi, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Gazyva
Treatment of previously untreated chronic lymphocytic leukaemia (CLL) and indolent non hodgkin lymphoma (iNHL)
Pharmac Funding Status of Gazyva:
Funded Previously untreated chronic lymphocytic leukaemia (CLL)
Funded Indolent non hodgkin lymphoma (iNHL)
See Pharmac websitefor more information.
If you would like to learn more about Gazyva, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Hemlibra
Treatment of congenital haemophilia A with or without factor VIII inhibitors
Pharmac Funding Status of Hemlibra:
Funded Congenital haemophilia A with factor VIII inhibitors
Funded Congenital haemophilia A without factor VIII inhibitors
See Pharmac websitefor more information.
If you would like to learn more about Hemlibra, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Polivy
For the treatment of certain patients with diffuse large B-cell lymphoma
Pharmac Funding Status of Polivy:
Not Funded Certain patients with diffuse large B-cell lymphoma
Polivy is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Polivy, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of VABYSMO
Treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and macular oedema secondary to retinal vein occlusion (RVO).
Pharmac Funding Status of VABYSMO
Not Funded Neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and macular oedema secondary to retinal vein occlusion (RVO).
VABYSMO is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about VABYSMO, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Evrysdi
Treatment of spinal muscular atrophy (SMA) in patients aged 2 months and older.
Pharmac Funding Status of Evrysdi:
Funded Spinal Muscular Atrophy 18 years old and under
Not Funded Spinal Muscular Atrophy over 18 years old
See Pharmac websitefor more information.
Evrysdi is not publicly funded by PHARMAC for all indications, which means some New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Evrysdi, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Madopar
Treatment of Parkinson’s disease
Pharmac Funding status of Madopar:
Funded Parkinson's Disease
See Pharmac websitefor more information.
If you would like to learn more about Madopar, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Ocrevus IV and Ocrevus SC
Treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)
Pharmac Funding Status of Ocrevus IV:
Funded Relapsing Forms of Multiple Sclerosis (for patients who meet defined criteria)
Funded Primary Progressive Multiple Sclerosis (for patients who meet defined criteria)
Pharmac Funding Status of Ocrevus SC
Not Funded for any indication
See Pharmac websitefor more information.
If you would like to learn more about Ocrevus IV and Ocrevus SC, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Alecensa
Treatment of locally advanced or metastatic ALK-positive non-small cell lung cancer.
Pharmac Funding Status of Alecensa
Funded Locally advanced or metastatic ALK-positive non-small cell lung cancer
See Pharmac webisitefor more information.
If you would like to learn more about Alecensa, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Avastin
Treatment of advanced (metastatic) bowel, kidney, breast, brain, lung, ovarian and cervical cancers
Pharmac Funding Status of Avastin
Not Funded Metastatic bowel cancer
Not Funded Metastatic kidney cancer
Not Funded Metastatic breast cancer
Not Funded Metastatic brain cancer
Not Funded Metastatic lung cancer
Not Funded Metastatic ovarian cancer
Not Funded Metastatic cervical cancer
Avastin is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients. These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Avastin, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Cotellic
Treatment of advanced (metastatic) melanoma
Pharmac Funding Status of Cotellic
Not Funded Metastatic melanoma
Cotellic is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Cotellic, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Erivedge
Treatment of advanced (metastatic) basal cell carcinoma
Pharmac Funding Status of Erivedge:
Not Funded Metastatic basal cell carcinoma
Erivedge is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Erivedge, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Herceptin SC
Treatment of HER2-positive early and metastatic breast cancer
Pharmac Funding Status of Herceptin SC:
Not Funded HER2-positive early and metastatic breast cancer
Herceptin SC is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Herceptin SC, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Herceptin IV
Treatment of HER2-positive early and metastatic breast cancer and for HER2-positive advanced gastric cancer.
Pharmac Funding Status of Herceptin IV:
Not Funded HER2-positive early and metastatic breast cancer
Not Funded HER2-positive early and metastatic breast cancer
Herceptin IV is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Herceptin IV, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Kadcyla
For the second-line treatment of HER2-positive metastatic breast cancer and adjuvant treatment in early HER2-positive breast cancer.
Pharmac Funding Status of Kadcyla:
Funded Second-line treatment of HER2-positive metastatic breast cancer
Funded Adjuvant treatment in early HER2-positive breast cancer
See Pharmac websitefor more information.
If you would like to learn more about Kadcyla, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Perjeta
Treatment of HER2-positive early breast cancer either before or after surgery (neoadjuvant or adjuvant) and advanced (metastatic) breast cancer
Pharmac Funding Status of Perjeta:
Not Funded HER2-positive early breast cancer either before or after surgery (neoadjuvant or adjuvant)
Funded Advanced (metastatic) breast cancer
See Pharmac websitefor more information.
Perjeta is not publicly funded by PHARMAC, which means some New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Perjeta, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Phesgo
For the treatment of HER2-positive early breast cancer and HER-2 positive metastatic or locally recurrent unresectable breast cancer, in combination with chemotherapy.
Pharmac Funding Status of Phesgo:
Not Funded HER2-positive early breast cancer and HER-2 positive metastatic or locally recurrent unresectable breast cancer, in combination with chemotherapy
Phesgo is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Phesgo, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of ROZLYTREK
Treatment of ROS1 positive locally advanced and metastatic non-small cell lung cancer
Treatment of NTRK-fusion positive locally advanced and metastatic solid tumours
Pharmac Funding Status of ROZLYTREK:
Not Funded ROS1 positive locally advanced and metastatic non-small cell lung cancer
Not Funded Certain patients with NTRK fusion-positive locally advanced or metastatic solid tumours
ROZLYTREK is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about ROZLYTREK, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Tecentriq and Tecentriq SC
Treatment of early and metastatic non-small cell lung cancer, extensive-stage small cell lung cancer, metastatic urothelial carcinoma, unresectable hepatocellular carcinoma, and metastatic triple-negative breast cancer.
Pharmac Funding Status of Tecentriq
Funded Locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received chemotherapy
Funded Hepatocellular carcinoma
Not Funded Urothelial cancer
Not Funded Triple negative breast cancer
Not Funded Other lung cancer indications
Pharmac Funding Status of Tecentriq SC
Not Funded for any indication
See Pharmac websitefor more information.
Tecentriq and Tecentriq SC are not publicly funded by PHARMAC for all indications, which means some New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Tecentriq and Tecentriq SC, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Zelboraf
Treatment of advanced (metastatic) melanoma.
Pharmac Funding Status of Zelboraf
Not Funded Advanced (metastatic) melanoma
Zelboraf is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
To help New Zealand patients access this medicine, we have developed a number of cost share programmes which are designed to reduce the cost to patients.
These programmes offer assistance with the cost of your medicine and often involve a cap being placed on either the number of doses or ‘cycles’ of the medicine, or the overall cost you pay. Your doctor can provide you with further information regarding the criteria for enrolling into one of the Roche Cost Share Programmes.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about Zelboraf, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Esbriet
Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Pharmac Funding Status of Esbriet:
Funded Idiopathic Pulmonary Fibrosis (IPF)
See Pharmac websitefor more information.
If you would like to learn more about Esbriet, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of NeoRecormon
Treatment of anaemia
Pharmac Funding Status of NeoRecormon:
Not Funded Anaemia
NeoRecormon is not publicly funded by PHARMAC, which means New Zealand patients are required to pay for this medication themselves.
Health Insurance
If you have health insurance, carefully check what is covered – every health insurance provider has different rules and benefits that cover treatment, surgery, tests and appointments.
If you would like to learn more about NeoRecormon, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Pulmozyme
Treatment of cystic fibrosis
Pharmac Funding Status of Pulmozyme:
Funded Cystic fibrosis
See Pharmac websitefor more information.
If you would like to learn more about Pulmozyme, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of CellCept
Treatment to prevent rejection of transplanted organs
Pharmac Funding Status of CellCept
Funded To prevent rejection of transplanted organs
See Pharmac websitefor more information.
If you would like to learn more about CellCept, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Medsafe Registered Uses of Tamiflu
Treatment of influenza
Pharmac Funding Status of Tamiflu:
National Reserve Supply (to be released for use in pandemic setting)
If you would like to learn more about Tamiflu, make an appointment with your doctor to discuss whether it’s the right treatment option for you.
More Information
Responsible Business
The promotion and sale of pharmaceutical and diagnostics products is highly regulated. Roche has a strong commitment to comply with all applicable laws, regulations and industry codes.
In New Zealand our business practices are regulated and guided by the following Acts and Codes.
Advertising Standards Authority Therapeutic and Health Advertising Code
The Medical Technology Association of New Zealand Code (MTANZ) Code of Practice.
Our Code of Conduct also guides our business practices.